✦ LIBER ✦

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

✍ Scribed by Wang, M.; Dimopoulos, M. A.; Chen, C.; Cibeira, M. T.; Attal, M.; Spencer, A.; Rajkumar, S. V.; Yu, Z.; Olesnyckyj, M.; Zeldis, J. B.; Knight, R. D.; Weber, D. M.

Book ID: 121662366
Publisher: American Society of Hematology
Year: 2008
Tongue: English
Weight: 159 KB
Volume: 112
Category: Article
ISSN: 0006-4971
DOI: 10.1182/blood-2008-02-141614

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of thalidomide-based therapy fo

Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

✍ Kukreti, Vishal; Masih-Khan, Esther; Young, Trieu; Chu, Chia-Min; Jiang, Haiyun; 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Effects of Lenalidomide and Dexamethason

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

✍ Jesús F. San-Miguel; Meletios A. Dimopoulos; Edward A. Stadtmauer; S. Vincent Ra 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 208 KB

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Impact of high-risk cytogenetics and pri

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

✍ Avet-Loiseau, H; Soulier, J; Fermand, J-P; Yakoub-Agha, I; Attal, M; Hulin, C; G 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 313 KB

Lenalidomide alone or in combination wit

Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells

✍ Minnema, M C; van der Veer, M S; Aarts, T; Emmelot, M; Mutis, T; Lokhorst, H M 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 110 KB

Long-term follow-up on overall survival

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

✍ Dimopoulos, M A; Chen, C; Spencer, A; Niesvizky, R; Attal, M; Stadtmauer, E A; P 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 164 KB